P/E at 30.73 vs Industry's 37.02: What the Data Shows for Dr Reddys Laboratories Ltd

1 hour ago

Share Via

A price-to-earnings ratio of 30.73 against an industry average of 37.02 reveals a notable valuation discount for Dr Reddys Laboratories Ltd. Previously rated Hold by MarketsMojo, the stock’s rating was reassessed on 13 Jul 2026. While the one-year return trails the Sensex, the short-term performance paints a more complex picture, highlighting divergent momentum across timeframes.

Valuation Picture: Discount Amidst Sector Premiums

Dr Reddys Laboratories Ltd trades at a P/E multiple of 30.73, which is approximately 17% below the Pharmaceuticals & Biotechnology industry average of 37.02. This discount suggests the market is pricing in either a more cautious outlook on earnings growth or risk factors specific to the company. Compared to peers, this valuation gap could indicate relative undervaluation, but it also raises questions about the sustainability of earnings and competitive positioning within the sector. Previously rated Hold, what is Dr Reddys Laboratories Ltd’s current rating? The valuation premium or discount is a critical factor in this reassessment.

Performance Across Timeframes: Mixed Momentum

The stock’s performance over the past year has been underwhelming, with a return of -6.22% compared to the Sensex’s -4.05%. This underperformance extends to the year-to-date period, where Dr Reddys Laboratories Ltd has declined by -6.79%, though this is marginally better than the Sensex’s -9.04% over the same period. The divergence becomes more pronounced over the three-month horizon, where the stock has fallen -10.18%, sharply contrasting with the Sensex’s positive 2.17% gain. This sharp short-term weakness contrasts with modest gains over the one-month (2.95%) and one-week (0.29%) periods, signalling a recent attempt at recovery within a broader downtrend. Is this a genuine recovery or a relief rally that will fade at the 50 DMA?

Moving Average Configuration: Signs of a Tentative Bounce

The technical setup for Dr Reddys Laboratories Ltd reveals a nuanced picture. The stock is currently trading above its 20-day moving average but remains below the 5-day, 50-day, 100-day, and 200-day moving averages. This configuration suggests a tentative bounce in the short term, yet the longer-term trend remains under pressure. The fact that the stock has been losing ground for three consecutive days, with a cumulative decline of -1.13%, adds to the uncertainty. The 20-day average support may be a short-term floor, but the resistance at longer-term averages indicates that the broader downtrend has not yet been decisively broken. Is this a recovery or a dead-cat bounce?

Relative Performance: Lagging the Sensex Over Longer Horizons

Examining longer-term returns, Dr Reddys Laboratories Ltd has lagged the Sensex significantly. Over three years, the stock returned 2.52% compared to the Sensex’s 19.46%, while over five years, it gained 28.75% against the Sensex’s 38.11%. The ten-year performance shows a similar pattern, with the stock up 94.87% versus the Sensex’s 179.01%. This persistent underperformance over extended periods highlights challenges in maintaining growth momentum relative to the broader market. However, the stock’s outperformance relative to the Sensex in the year-to-date period suggests some recent resilience despite the overall negative trend. Should investors in Dr Reddys Laboratories Ltd hold, buy more, or reconsider?

Sector Context: Mixed Results in Pharmaceuticals & Biotechnology

The Pharmaceuticals & Biotechnology sector has seen mixed results in recent earnings announcements. Out of 34 stocks that have declared results, 14 reported positive outcomes, 15 were flat, and 5 posted negative results. This distribution indicates a sector grappling with uneven performance, reflecting varied company-specific factors and broader industry challenges. Within this context, Dr Reddys Laboratories Ltd’s performance and valuation discount may be symptomatic of sector-wide pressures as well as company-specific dynamics. How does this sector performance influence Dr Reddys Laboratories Ltd’s outlook?

Rating Context: Previously Rated Hold, Now Reassessed

The rating for Dr Reddys Laboratories Ltd was updated on 13 Jul 2026, moving from a previous Hold rating. This reassessment reflects the evolving valuation and performance data, including the stock’s discount to industry P/E, recent underperformance relative to the Sensex, and its mixed technical signals. The Mojo Score currently stands at 30.0, indicating a cautious stance. The rating update underscores the importance of integrating multiple data points — valuation, momentum, and sector trends — in evaluating the stock’s position. What is the current rating for Dr Reddys Laboratories Ltd following this reassessment?

Conclusion: A Complex Data Story Demanding Nuanced Analysis

The data for Dr Reddys Laboratories Ltd presents a multifaceted picture. The stock trades at a meaningful discount to its sector’s P/E, suggesting valuation appeal tempered by concerns reflected in its recent underperformance and technical setup. Short-term momentum shows tentative signs of recovery, yet longer-term moving averages and multi-year returns highlight persistent challenges. The sector’s mixed earnings results add further complexity to the assessment. The rating update from Hold to a new status reflects these nuanced factors. Should investors reconsider their stance on Dr Reddys Laboratories Ltd in light of this data?

Get 33% Off on our 1 Year Plan - Limited Period Only! Start Today

{{stockdata.stock.stock_name.value}} Live

{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)

{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)

MOJO SCORE